Analyst downgrades typically lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The downgrade from Buy to Hold suggests that Maxim Group sees limited upside potential or increased risks that could hamper Agile Therapeutics' stock performance in the near term.